nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2013 | Original Article

High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma

verfasst von: Raghava Kashyap, Eddie Lau, Anupkumar George, John F. Seymour, Stephen Lade, Rodney J. Hicks, Michael S. Hofman

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis.

Methods

We identified 16 patients from 8,819 restaging FDG PET/CT scans with suspicion of or biopsy-proven fat necrosis on PET/CT.

Results

All patients had NHL and demonstrated focal FDG-avid nodular change on CT with density higher than that of fat but lower than that of soft tissue. Histological confirmation was obtained in eight patients, with high GLUT-1 staining between necrotic tissue and organizing fat necrosis evident. Uptake resolved in four patients, and surveillance was continuing in four without relapse.

Conclusion

Although rare, identification of fat necrosis in patients with a solitary FDG-avid nodule after therapy is important and may lead to the avoidance of unnecessary interventions or treatment. Specific features on CT aid identification, whilst follow-up imaging can be helpful as the metabolic abnormality regresses with time.

Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med. 2011;25:701–16. doi:10.1007/s12149-011-0549-0.PubMedCrossRef

MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10–8. doi:10.1102/1470-7330.2007.0004.PubMedCrossRefPubMedCentral

Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med. 2005;35:165–75. doi:10.1053/j.semnuclmed.2005.02.003.PubMedCrossRef

Hofman MS, Smeeton NC, Rankin SC, Nunan T, O’Doherty MJ. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009;50:1594–7. doi:10.2967/jnumed.109.064121.PubMedCrossRef

McDermott S, Skehan SJ. Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging. 2010;35:55–69. doi:10.1007/s00261-008-9493-4.PubMedCrossRef

De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, et al. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging. 2009;34:696–711. doi:10.1007/s00261-008-9457-8.PubMedCrossRef

Kapoor V, Fukui MB, McCook BM. Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. AJR Am J Roentgenol. 2005;184:589–97.PubMedCrossRef

Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:1348–55. doi:10.1007/s00259-012-2143-7.PubMedCrossRef

Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–8.PubMedCrossRef

10.

Ng AP, Wirth A, Seymour JF, Lee M, Hogg A, Januszewicz H, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007;48:596–600. doi:10.1080/10428190601099965.PubMedCrossRef

11.

Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81. doi:10.3109/10428194.2012.677535.PubMedCrossRef

12.

Adejolu M, Huo L, Rohren E, Santiago L, Yang WT. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol. 2012;198:W304–14. doi:10.2214/AJR.11.7130.PubMedCrossRef

13.

Belakhlef A, Jani C, Church C, Fraser R, Lakhanpal S. Fat necrosis mimicking B-cell lymphoma: a PET/CT and FDG study. Clin Nucl Med. 2008;33:271–2. doi:10.1097/RLU.0b013e3181662bbf.PubMedCrossRef

14.

Singh AK, Gervais DA, Lee P, Westra S, Hahn PF, Novelline RA, et al. Omental infarct: CT imaging features. Abdom Imaging. 2006;31:549–54. doi:10.1007/s00261-005-0251-6.PubMedCrossRef

15.

Daskalogiannaki M, Voloudaki A, Prassopoulos P, Magkanas E, Stefanaki K, Apostolaki E, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol. 2000;174:427–31.PubMedCrossRef

16.

Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics. 2003;23:1561–7. doi:10.1148/rg.1103035010.PubMedCrossRef

17.

Canyigit M, Koksal A, Akgoz A, Kara T, Sarisahin M, Akhan O. Multidetector-row computed tomography findings of sclerosing mesenteritis with associated diseases and its prevalence. Jpn J Radiol. 2011;29:495–502. doi:10.1007/s11604-011-0587-5.PubMedCrossRef

18.

Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol. 2006;79:37–43. doi:10.1259/bjr/29320216.PubMedCrossRef

19.

Joerger M, Nuessli DF, Henz S, Zaunbauer W, Cerny T, Cogliatti SB, et al. CT-diagnosed mesenteric alterations in patients with non-Hodgkin’s lymphoma: a population-based study. Onkologie. 2008;31:514–9. doi:10.1159/000151624.PubMedCrossRef

Titel: High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma
verfasst von: Raghava Kashyap
Eddie Lau
Anupkumar George
John F. Seymour
Stephen Lade
Rodney J. Hicks
Michael S. Hofman
Publikationsdatum: 01.09.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2013
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2429-4

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2013

Reply to: Area under the cumulative SUV-volume histogram is not a viable metric of intratumoral metabolic heterogeneity

68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma

Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia

[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches

In memoriam: Ludwig G. Strauss, MD, 1949–2013

RETRACTED ARTICLE: Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging